Ibrutinib Blocks YAP1 Activation and Reverses BRAF Inhibitor Resistance in Melanoma Cells

Sean A. Misek; Patrick A. Newbury; Evgenii Chekalin; Shreya Paithankar; Andrea I. Doseff; Bin Chen; Kathleen A. Gallo; Richard R. Neubig

doi:10.1124/molpharm.121.000331

Research ArticleArticle

Ibrutinib Blocks YAP1 Activation and Reverses BRAF Inhibitor Resistance in Melanoma Cells

Sean A. Misek, Patrick A. Newbury, Evgenii Chekalin, Shreya Paithankar, Andrea I. Doseff, Bin Chen, Kathleen A. Gallo and Richard R. Neubig

Molecular Pharmacology January 2022, 101 (1) 1-12; DOI: https://doi.org/10.1124/molpharm.121.000331

Sean A. Misek

Departments of Physiology (S.A.M., A.I.D., K.A.G.), Pediatrics and Human Development (P.A.N., E.C., S.P., B.C.), and Pharmacology (A.I.D., B.C., R.R.N.), Michigan State University, East Lansing, Michigan

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Patrick A. Newbury

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Evgenii Chekalin

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Shreya Paithankar

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Andrea I. Doseff

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Bin Chen

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Kathleen A. Gallo

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Richard R. Neubig

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Info & Metrics
eLetters
PDF

Submit a Response to This Article

Compose eLetter

Title *

Contents

More information about text formats

Plain text

No HTML tags allowed.
Web page addresses and e-mail addresses turn into links automatically.
Lines and paragraphs break automatically.

Author Information

Contributors
First Name and Middle Initial * First or given name, e.g. 'Peter'. Last Name * Your last, or family, name, e.g. 'MacMoody'. Email Address * Your email address, e.g. higgs-boson@gmail.com Occupation * Your role and/or occupation, e.g. 'Orthopedic Surgeon'. Affiliation * Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.

Statement of Competing Interests

Competing interests? *

Yes

Please describe the competing interests

Vertical Tabs

Jump to comment:

No eLetters have been published for this article.

PreviousNext

In this issue

Molecular Pharmacology

Vol. 101, Issue 1

1 Jan 2022

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author
Editorial Board (PDF)
Front Matter (PDF)

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Ibrutinib Blocks YAP1 Activation and Reverses BRAF Inhibitor Resistance in Melanoma Cells

Message Subject (Your Name) has forwarded a page to you from Molecular Pharmacology

Message Body (Your Name) thought you would be interested in this article in Molecular Pharmacology.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Citation Tools

Research ArticleArticle